INTRODUCTION
The recent availability of techniques for measuring triiodothyronine (Ts)1 in human serum has provoked new interest in this thyroid hormone (1) (2) (3) . It is speculated that Ts may provide as much as 50-60% of the body's thyroid hormone requirements (2) . Because of the apparent importance of this hormone, we have been interested in the effects of various drugs which might interfere with binding of Ts to the proteins in human serum leading to subsequent increases in the free form of this hormone.
Extensive prior investigations with thyroxine (T4) have shown that the small, unbound fraction, free To, is the most satisfactory peripheral index of the thyroid status (4) . It is postulated that free T4 is the only, or at least the most readily available, fraction of To present in extracellular fluid that can be utilized by the cells. Similar theoretical arguments are applicable to free Ts. Therefore, agents which interfere with the binding of Ts to its binding proteins would lead to at least a temporary increase in free Ts. This might be expected to increase the amount of Ts available to peripheral tissues 1Abbreviations used in this paper: DPH, diphenylhydantoin; Ta, triiodothyronine; T4, thyroxine; TBG, thyroxine-binding globulin; TBPA, thyroxine-binding prealbumin; UFTa and UFT4, ultrafiltrable fraction of tracer hormones in serum after labeling with T, and T., respectively.
The Journal of Clinical Investigation Volume 51 1972 and perhaps, because of the rapid onset and high potency of Ts, to cause hypermetabolism.
Previous studies have shown that salicylate and its congeners decrease the binding of To to the binding proteins in human serum (5) (6) (7) . These drugs were found to interfere specifically with the binding of To to thyroxine-binding prealbumin (TBPA). This conclusion was largely based on the alterations in the distribution of labeled To after paper electrophoresis of human serum. Since Ts is not thought to be bound to TBPA, we anticipated that addition of salicylate to human serum would cause an increase in free To with no change in free Ts. Administration of this drug might, therefore, offer a way to compare the effects of changes in the free form of only one of the two thyroid hormones. However, preliminary studies showed that addition of sodium salicylate to human serum caused an increase in free Ts that was nearly as great as the salicylate-induced increase in free T4. Simultaneous experiments with serum enriched with To showed that the increased free Ts induced by salicylates could not be explained by displacement of T. from TBPA to TBG. The salicylate effect on free Ts suggested either that this drug could interfere with TBG-T8 interaction or that Ts was, in fact, bound to TBPA, or, perhaps, both. This seemed inconsistent with the previously mentioned conclusions. The following studies were performed to clarify the mechanism of action of salicylate on the protein binding of the two thyroid hormones.-
METHODS
Free triiodothyronine and free thyroxine. These values were estimated by determining the ultrafiltrable fraction (UFT3 and UFT4) of tracer hormones present after enrichment of human serum with labeled Ts and T4 by methods previously described (8) . In order to obtain simultaneous measurements, Ta-`I, 0.05-0.20 ,Ag/100 ml, and TAX'I, [1] [2] [3] ,tg/100 ml serum were added. Both isotopes were obtained from Abbott Laboratories, North Chicago, Ill. The Tr-'I preparations used contained less than 0.3% Tr-wI as a contaminant as determined by paper chromatography in tertiary amyl alcohol-hexane-NH4OH by methods described previously (9 (11) . The normal range in our laboratory is 4.5 -12 ,ug T4/100 ml serum. The values are corrected for the 80%o yield in the ethanol extraction step. The values for absolute free Ta and free T4 were determined by multiplication of the ultrafiltrable fraction by the concentration of total hormone. In the sequential studies of the effects of aspirin administration, all determinations of each parameter were carried out simultaneously to minimize technical variations.
In the studies performed to demonstrate displacement of Ts and T4 from TBG, methods identical with those previously described for quantitation of Ta using TBG were used (9) . In this system, 4% human serum in glycine-acetate or barbital buffer, pH 8.6, is enriched with tracer Ts and T4. mg/100 ml) or toxic (60, or greater, mg/100 ml) ranges observed in man.
For further comparison the effects of the addition of diphenylhydantoin (DPH) are also shown. This agent causes both displacement of T4 and presumably Ts from TBG (6) . At therapeutic levels (10-20 ug/ml), DPH addition results in considerably less dramatic increases in UFT, and UFT4 though the changes are statistically significant (P < 0.05 at 10 Ag/ml, P < 0.01 at 20 and 40 ,g/ml).
Effect of dilution of human serum containing salicylate on UFTs and UFT4. It would be anticipated from the mass law equations that dilution of a weakly bound ligand would decrease its competition with one more firmly bound. For example, dilution of serum containing DPH results in a marked decrease in the apparent effect of this agent on T. binding in human serum (15) . A similar phenomenon was observed with sodium salicylate (Fig. 2) . In these studies, control and salicylateenriched human sera were progressively diluted as indicated and UFT8 and UFT4 determinations made simultaneously. There is a progressive decrease in the apparent effect of salicylate with dilution which is significant for UFTs even at a 1: 2 dilution. The increase in both UFTa and UFT4, over twofold in the undiluted control specimen, is nearly eliminated at a 1: 50 dilution of human serum. These studies underline the necessity for performing studies of weak binding inhibitors in whole serum. In addition, these data demonstrate that the effect of salicylates on the UFTa and UFT4 is reversible.
Comparison of the effects of sodium salicylate and barbital on the binding of T. and T4 in human serum and to human serum albumin. Since the results of previous studies argued against an effect of salicylate either on interference with Ta-TBG binding or Ts-TBPA binding, we initially examined the effect of this agent on albumin-Ts binding. Both salicylate and the thyroid hormones are known to be bound to this protein. In addition, the effects of barbital, another agent previously demonstrated to interfere with the binding of To to TBPA, were compared with those of salicylate (7). For technical reasons, diluted serum or human serum albumin was used in these studies and sodium salicylate was added to a final concentration of 15 mg/100 ml. In the first entry of Table I , it is seen that both salicylate and barbital cause an increase in the UFT4. The increase in UFT4 after dilution of serum in barbital buffer is somewhat greater than that caused by salicylate; however, this may be only a matter of concentration differences. The inhibitory effect of salicylate and barbital on albumin-T4 binding is considerably greater than that in serum as would be anticipated. The effect of salicylate and barbital on the binding of Ts in human serum is similar to the effects of these agents on To binding. Thus, both salicylate and barbital displace Ts from its binding proteins. However, it is clear from the last entry in Table I that the effect of these agents on T8 binding in whole serum cannot be explained by inhibition of Ts binding to human serum albumin. The per cent increase in the UFTs caused by salicylate and barbital is less with purified human albumin than it is with whole serum. Thus, it (Table II) . While Ts is bound to human TBPA as indicated by the UFT3 of < 1.0, the binding was considerably less strong than that of T4. Paper electrophoretic studies of the commercial preparation of TBPA after addition of tracer quantities of TAXI did not show any evidence of TBG contamination. As a control for these studies, similar concentrations of human serum albumin were tested. The binding of Ts to TBPA seems to be slightly greater than the binding of Ts to human serum albumin as indicated by the higher UFT3 in the presence of albumin. It is seen that both the UFT* and UFT4 are increased by salicylate addition to either protein solution indicating this compound interferes with Ts amounts of Ts,T4 or sodium salicylate, 1-ml samples of the mixture were equilibrated overnight and then bound and free hormones were separated by addition of dextrancoated charcoal. As is seen in Fig. 3 , both Ta and T4 displace the labeled iodothyronines from the binding proteins present in human serum. In addition, sodium salicylate readily displaces Ta and, at higher concentrations, To from these binding proteins. While physicochemical considerations suggest that TBG is the only binding protein present in human serum with a sufficiently high affinity for Ts and T4 to act as a competitive binding protein, it was necessary to prove this conclusively. It has been demonstrated by Pensky and Marshall that TBG can be isolated from human serum using affinity chromatography with To coupled to Sepharose (Pharmacia Fine Chemicals, Inc., Uppsala, Sweden) (19) . Applying the same principle, T4-Sepharose, prepared as described by these authors, was added to human serum and incubated at 4VC overnight with stirring. Comparison of paper electrophoretic patterns after addition of T4AI in tracer amounts showed that TBG binding was almost eliminated in serum treated in this way (Fig. 4) . If FIGURE 4 Distribution of tracer T4 in human serum before and after TBG adsorption with T4-Sepharose. Reverse flow electrophoresis of serum was performed in glycine-acetate buffer pH 8.6 after addition of tracer quantities of T4-'I (< 2 ,ug/100 ml).
Free Triodothyronine and Salicylates area of the T4-Sepharose adsorbed sera are due to TBGbound TJ, by planimetry, it represents less than 8% of the original TBG-binding capacity.
TBPA-binding capacity in serum was unchanged by T4-Sepharose adsorption and the TA concentration increased only 2 .g/100 ml. The latter occurred due to the fact that even with repeated attempts to purify the T,-Sepharose, small quantities of presumably noncovalently bound To adhere to the material and are subsequently bound to the serum proteins. It is obvious that enrichment of serum with large quantities of T4, such as might occur with unwashed Td-Sepharose preparations, could lead to a similar decrease in the percentage of tracer bound to TBG that is shown in Fig. 4 (though one would expect to see much greater binding in the albumin area under these conditions).
Since the same serum could be compared before and after TBG elimination, its role in this assay system could be clarified. Table III shows comparison of Ts and To binding of these sera in both glycine-acetate and barbital buffer in the same system described for Fig. 3 . It is apparent that the binding of Ts is inhibited by barbital. There is also slight inhibition of T. binding in barbital buffer. After removal of TBG, the per cent T3 bound falls to a level of 13.3 in glycine acetate and 6.5 in barbital buffer demonstrating that TBG is the critical Ts-binding protein in this system. While there is a significant decrease in the per cent T. bound after removal of TBG, it is only after inhibition of TBPA and albumin binding in barbital buffer that the importance of TBG-Td binding in this system is observed. The control data demonstrate that there is no significant difference in the two systems with respect to the binding of free tracer to the dextran-charcoal in the absence of serum. The data in Table III show that in this system (the same as that of Fig. 3 ), a maximum of about 6.5% of the tracer T3-l'I is bound to TBPA and albumin and likewise about 22.6% of the tracer T4 is bound to these two proteins under base line conditions. Therefore, any decrease in the percentage of tracer T8 bound greater than 6.5% and of T4 greater than 22.6% implies interference with TBG binding of these two hormones. Since sodium salicylate at 6 X 10' M causes a net displacement of about 41% of the Ta-'I and at 6 X 1o-' M displaces about 52% of the T4-'1I (Fig. 3) (20) . If salicylates interfere with TBG-T4 and Ta binding one would anticipate a decrease in the total Ta and To and increases in the UFT5 and UFT4. We have studied the effects of aspirin administration in two subjects under controlled conditions. Three base line determinations were obtained during a 6 day control period. Specimens during aspirin administration were obtained every other day over a subsequent 8 to 10 day period. There was an immediate and persistent increase in the UFTs and UFT4 in both subjects. Fig. 5 shows the relationship of these changes to the salicylate levels in one of these. Maintenance of a salicylate concentration on the order of 20-25 mg/100 ml was associated with increases in the free fraction comparable to those obtained in vitro at this concentration. Unlike what has been observed during DPH therapy, this increase in the free fraction of both T3 and To appears to be maintained (8, 15) . FTs  T4  UFT4  FT4  Ts  UFTa  FT3  T4   UFT4  FT4 ng/ml X10-' ng/100 ml 1Ag/100 ml X10-4 ng/100 ml nag/ml X10-ng/100 ml pg/100 ml X10-4 ng/100 ml In Table IV are shown the effects of aspirin administration on the absolute free Ts and free T4 in the two subjects. While it is difficult to know whether it is accurate to average the samples during the entire treatment period due to disequilibrium conditions, this has been done for the purposes of these initial studies. With regard to Ts levels, there is a suggestion of a decrease in the total amount of Ts to about 76% of control in both subjects. This compensates to some extent for the increased UFTs resulting in an average increase in free T3 of only about 23% in these subjects. The decrease in T4 is substantial, about 25-30%, similar to the effect of DPH therapy (8, 15, 21) . Again this compensation results in only a slight increase in the absolute free T4. These two studies were carried out for a period of about 8 to 10 days of salicylate administration. Longer periods of aspirin treatment will be necessary to determine whether this slightly elevated free hormone concentration persists under steady-state conditions. DISCUSSION The above data indicate that sodium salicylate interferes with Ts and T. binding to TBG. This interference was first demonstrated in human serum by Osorio in 1962 (22) . In these studies, paper electrophoresis was used but subsequent studies using this technique have emphasized only the salicylate effect on TBPA-T4 binding (7) .
Apparently, the effect of salicylates on the distribution of labeled hormones during paper electrophoresis is markedly greater on TBPA than it is on TBG. Thus, a different system is desirable to demonstrate the magnitude of the inhibition of TBG binding of Ts and T4. This could conceivably be done in paper electrophoretic studies with serum completely devoid of TBPA.
While surprising in light of current concepts, one could predict the interference of salicylates with Ta and T& binding to TBG from theoretical considerations based on recently available data. Woeber and Ingbar have shown that complete elimination of TBPA by immunoadsorption increases the free T4 only an average of 22% (23) . Yet at a concentration of 60 mg salicylate/100 ;ml, the UFT4 in our system is increased 241%. Therefore, salicylate inhibition of TBPA binding is not playing a major role at this salicylate level. In addition, using assumptions based on the data of these and other investigators regarding T4 distribution and current estimates of affinity constants for the various binding proteins, one can calculate the theoretical effect of complete elimination of TBPA and albumin binding using the mnass action equation developed by Robbins and Rall (reference 4, see Appendix). Using this formula, one estimates that after complete inhibition of T, binding to both albumin and TBPA, there will be only a 30% increase in the free T4. This emphasizes the importance of TBG-binding in the determination of the amount of T4 that is free. Thus, at higher salicylate levels, interference with TBG-T4 binding must be a factor and it is presumably present at lower concentrations to some extent as well. Since the affinity of T3 for all the binding proteins is considerably less than that of T4, Ta-TBG interaction will be inhibited at lower salicylate levels.
The per cent increase in free T4 due to salicylate addition is moderately greater than that in free Ts (241% vs. 155% at 60 mg/100 ml salicylate). However, the fraction of bound Ts displaced by salicylate is greater than that of T. This would be anticipated from the data in Fig. 3 and is a result of the lower binding affinity of T3 vs. T4 for TBG. This can be quantitated by comparing the net increase in the UFT8 in the presence of 60 mg/100 ml salicylate (approximately 6.7 X 10-3) with the net increase in the UFT& (approximately 5.3 X 10').
The ratio of the two fractional increases is about 13: 1, UFTs: UFTi. Nevertheless, the original fraction of Ts free is about 20-fold greater than the fraction of To free (4.3 X 10' vs. 2.2 X 10', Fig. 1 ). Therefore, sodium salicylate does cause a disproportionate increase in UFT4 compared with the base line relationships. This could be a result of salicylate interference with T4-TBPA binding which is probably more quantitatively significant than T3-TBPA binding. It is postulated that T8 and T4 are bound to the same site on TBG (18) . In a simple system containing a single protein with one binding site, the free To: Ts ratio should remain constant in the presence of a competitive binding inhibitor.
The at least temporary increases in free Ts and free T4 in human subjects during 1 wk of aspirin therapy is of considerable interest both clinically and theoretically. For many years the similarity of the effects of salicylate and thyroid hormones on oxygen consumption have been recognized (24) . This similarity of action extends even to the demonstration in rats that salicylate will, at least temporarily, suppress TSH (25) . If free hormone is an index of the quantity of thyroid hormone available to the cells, then elevation of free T&, and particularly free T3 with its more rapid action and greater potency, may lead to symptoms of hyperthyroidism. While it is recognized that salicylates have T4-like effects on subcellular organelles, e.g. to uncouple oxidative phophorylation in mitochondria, the possibility that increases in the utilization of Ta and T4 due to unbinding of these hormones from their binding proteins also occurs during salicylate therapy cannot be excluded (26) . The most likely situation in which this could occur would be during salicylate intoxication in children where levels of 50-100 mg/100 ml salicylate are commonly seen. We are currently evaluating the possible significance of drug-induced hyperthyroidism in these patients. It is to be emphasized that at new steady-state concentrations of salicylate, T3, and T4, a return to pretreatment levels of absolute free Ts and free To concentrations would be anticipated. As pointed out previously under Results, the small increase in absolute free hormone over the 1st wk of therapy may only be temporary. Only if salicylates affect some other, perhaps cellular, binding site, could a persistent increase in free hormone occur. If only extracellular binding proteins are affected, one would anticipate that the increases in UFTs and UFT4 would be completely balanced by decreases in total T. and T4. There is evidence that this is occurring in these two subjects and that only more time would be required for complete equilibration.
The inability of previous investigators to demonstrate Ts binding to TBPA is not surprising in that studies of this hormone using various 
APPENDIX
The expression describing the concentration of free T4 originally formulated by Robbins and Rall is as follows (4) where (T4) = free T4, KTBG, KTBPA, KALB are the binding affinity constants for the respective proteins, (TBG), (TBPA), and (ALB) are the concentrations of unoccupied binding sites on the three binding proteins and T4.TBG, T4 TBPA and T4 ALB are the concentrations of T4 bound to the respective binding proteins. All concentrations are moles/liter. The following affinity constants, binding capacities, and distribution of T4 are assumptions based on previously published data using a T4 concentration of 7.7 isg/l00 ml (16, 18, 23 After complete inhibition of T4 binding to TBPA and albumin, the following conditions obtain in vitro:
(T4) = 10 X 10-8 M (1.6 X 1010) (16 X 10-8) and (T4) = 3.9 X 10-11 and UFT4 = 3.9 X 10-. 10 X10-8 Therefore, the relative increase in UFT4 predicted based on current estimates of the binding affinities and protein concentrations can be calculated: 3.9 X 10-4 3.0 X 1_-X 100 = 130% of original value.
